Bendeka (Bendamustine HCl) Patent Expiration, LOE Window & CMS Spending

Bendeka (Bendamustine HCl) by Eagle: FDA Orange Book LOE 2033-03-15, 0 AB generics, $8.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEagle
FDA Application & PathwayN208194 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-03-15
Orange Book Patents (*PED Extensions)20 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$8.9M
2024 Medicare Part D Spend$1.5M
2024 Medicaid Spend$7.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel